Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
28°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Agenus Inc.
< Previous
1
2
Next >
Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers
December 18, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs
December 05, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment
November 27, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development
November 12, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024
November 07, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus to Provide Third Quarter 2024 Financial Report and Corporate Update
November 05, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Botensilimab/Balstilimab Clinical Responses in Refractory Sarcomas Presented at ESMO 2024
September 13, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Botensilimab/Balstilimab Clinical Activity in Refractory Sarcomas to be Presented in Oral Session at ESMO 2024
September 09, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus to Participate in September Investor Conferences
September 03, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus Reports Second Quarter 2024 Operational and Financial Results
August 08, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus Announces Appointment of Tom Harrison to Board of Directors
August 08, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus Publishes Seminal Study on Botensilimab’s Activity in Treatment-Resistant Cancers
August 07, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus to Provide Second Quarter 2024 Financial Report and Corporate Update
July 26, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus Announces End-of-Phase-2 Meeting Outcomes and Topline Interim Phase 2 Data for BOT/BAL in MSS Colorectal Cancer
July 18, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Significant Tumor Reductions in Neoadjuvant MSS Colon Cancer Patients Treated with Botensilimab/Balstilimab Presented at ESMO GI Conference
June 28, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Cancer Therapy Evaluation Program Announces Availability of Botensilimab for Clinical Studies
June 27, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus Announces Appointment of Dr. Jennifer Buell to Its Board of Directors
June 17, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus Announces Virtual Annual Shareholders Meeting
June 04, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 24, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Breakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual Meeting
May 23, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
May 23, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for Relapsed or Refractory Metastatic Colorectal Cancer
May 16, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus Reports First Quarter 2024 Results
May 07, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus Regains Compliance with Nasdaq Minimum Bid Price Requirement
May 01, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Botensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting
April 24, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus to Provide First Quarter 2024 Financial Report and Corporate Update
April 23, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer
April 12, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus Announces Reverse Stock Split of Common Stock
April 05, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus Reports Fourth Quarter and Full Year 2023 Results
March 14, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024
March 06, 2024
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.